2 weeks Ago By ABMN Staff
ResMed Inc. ( NYSE:RMD – Get Free Report ) has been given an average rating of “Moderate Buy” by the fifteen analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company.
The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $250.08. RMD has been the topic of a number of research reports.
JPMorgan Chase & Co. increased their target price on shares of ResMed from $270.00 to $286.
00 and gave the stock an “overweight” rating in a report on Friday, January 31st. The Goldman Sachs Group initiated coverage on ResMed in a research note on Thursday, January 16th. They set a “buy” rating for the company.
Mizuho set a $265.00 target price on shares of ResMed in a research note on Wednesday, April 16th. Stifel Nicolaus dropped their price target on shares of ResMed from $250.
00 to $240.00 and set a “hold” rating on the stock in a research note on Wednesday, March 5th. Finally, Morgan Stanley initiated coverage on ResMed in a report on Wednesday, March 19th.
They issued an “overweight” rating and a $280.00 target price for the company. Check Out Our Latest Stock Report on ResMed Insider Transactions at ResMed Institutional Investors Weigh In On ResMed Several large investors have recently made changes to their positions in the stock.
Vanguard Group Inc. grew its position in ResMed by 0.9% in the fourth quarter.
Vanguard Group Inc. now owns 18,173,462 shares of the medical equipment provider’s stock valued at $4,156,089,000 after purchasing an additional 160,590 shares in the last quarter. Geode Capital Management LLC grew its holdings in ResMed by 2.
2% in the 4th quarter. Geode Capital Management LLC now owns 3,944,084 shares of the medical equipment provider’s stock valued at $899,860,000 after buying an additional 85,270 shares in the last quarter. Invesco Ltd.
boosted its holdings in ResMed by 32.2% in the 4th quarter. Invesco Ltd.
now owns 2,325,009 shares of the medical equipment provider’s stock valued at $531,706,000 after purchasing an additional 566,046 shares during the period. Northern Trust Corp raised its holdings in ResMed by 20.6% in the 4th quarter.
Northern Trust Corp now owns 1,702,590 shares of the medical equipment provider’s stock valued at $389,365,000 after acquiring an additional 290,664 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of ResMed by 3.
6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 957,020 shares of the medical equipment provider’s stock worth $218,861,000 after acquiring an additional 32,973 shares in the last quarter.
Institutional investors own 54.98% of the company’s stock. ResMed Price Performance RMD opened at $211.
04 on Friday. The firm has a market cap of $30.99 billion, a price-to-earnings ratio of 24.
92, a PEG ratio of 1.53 and a beta of 0.75.
The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.
13. The company has a fifty day simple moving average of $222.61 and a 200 day simple moving average of $234.
30. ResMed has a twelve month low of $178.49 and a twelve month high of $263.
05. ResMed ( NYSE:RMD – Get Free Report ) last issued its earnings results on Thursday, January 30th. The medical equipment provider reported $2.
43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.29 by $0.14.
ResMed had a net margin of 25.34% and a return on equity of 26.17%.
Equities research analysts expect that ResMed will post 9.47 EPS for the current fiscal year. ResMed Announces Dividend The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th.
Investors of record on Thursday, February 13th were given a dividend of $0.53 per share. The ex-dividend date was Thursday, February 13th.
This represents a $2.12 annualized dividend and a yield of 1.00%.
ResMed’s dividend payout ratio (DPR) is 25.03%. ResMed Company Profile ( Get Free Report ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets.
The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. Read More Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.
com's FREE daily email newsletter ..
